SecBot SecBot
8-K ·Filed Nov 12, 2026

SGP

SpyGlass Pharma, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4d 17h ago SEC0001778922-26-000055
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor Phase 3 enrollment progress and BIM-DRS preliminary data expected in 2027; the AVS acquisition secures commercial manufacturing but adds integration risk. Cash runway through 2028 provides ample time to reach data milestones.

DirectionNeutral
Confidencehigh
Horizonmonths

Drug in focus

SGP drug pipeline →

Bimatoprost Drug Pad-IOL System

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
Phase 3 trials are enrolling now; topline data expected in 2027. If successful, a 505(b)(2) NDA submission would follow, with potential FDA approval possibly in 2028-2029.
Next catalyst
None dated

What to watchWatch for Phase 3 topline readout (expected in 2027, no precise date yet) as the defining binary catalyst. The FIH 4-year data (Oct 2026) de-risks Phase 3 replication risk somewhat, but Phase 3 results will determine whether the 505(b)(2) NDA submission proceeds. Also monitor FDA alignment updates and any accelerated enrollment announcements.

Price Chart

Loading chart...

Executive Summary

SpyGlass Pharma reported Q3 2026 net loss of $24.3M ($0.73/share), wider than the $9.8M loss in Q3 2025, driven by increased R&D and G&A spending. The company highlighted positive clinical milestones: four-year BIM-IOL System follow-up data showing 86% of patients off topical drops, completion of first BIM-DRS implantations, and the $13M acquisition of IOL manufacturer AVS. Cash of $215.8M is expected to fund operations through 2028.

Key Financial Metrics

EPS
−$0.73

Key Facts

  • Q3 2026 net loss of $24.3M versus $9.8M in Q3 2025
  • Cash, cash equivalents and short-term investments of $215.8M as of September 30, 2026
  • Acquired Advanced Vision Science, Inc. for approximately $13M in cash
  • Four-year BIM-IOL System FIH data: 86% of patients off topical drops, 37% mean IOP reduction
  • First implantations completed in BIM-DRS FIH trial
  • Phase 3 enrollment on track for completion in 2027
  • R&D expenses $10.0M (Q3 2026) vs $8.1M (Q3 2025)
  • G&A expenses $16.2M (Q3 2026) vs $3.0M (Q3 2025)

Financial Impact

Net loss widened by $14.5M year-over-year to $24.3M; cash burn rate increased to ~$28.5M per quarter (from $9.8M net loss in Q3 2025 plus acquisition spend)

net losscashoperating expenses

Risk Factors

  • Pre-revenue stage with widening net losses and no approved products
  • Phase 3 trial results and regulatory approval for BIM-IOL System are uncertain
  • BIM-DRS is in early clinical stage with no efficacy data yet
  • Acquisition integration costs and manufacturing scale-up execution risk

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001778922-26-000055
Document: sgp-20261111.htm0001778922-26-000055
Document: 0001778922-26-000055-index-headers.html0001778922-26-000055
Document: 0001778922-26-000055-index.html0001778922-26-000055
Document: 0001778922-26-000055.txt0001778922-26-000055
8-K Data (Synthetic)0001778922-26-000055

US Market Status

Market Closed · Opens in 7h 56m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026